The global neuromodulation devices market size is expected to reach USD 10.39 billion by 2030, registering a CAGR of 8.51% from 2025 to 2030. The market's growth can be attributed to factors such as rising prevalence of neurological disorders, rising government support to R&D and development of advanced solutions with increased range of applications.
Significant funding from government and private agencies plays a crucial role in advancing the understanding of neurological disorders and improving treatment options. By allocating resources to research initiatives, governments actively facilitate groundbreaking discoveries, encourage technological innovations, and promote the development of more effective neuromodulation technologies. For instance, in August 2024, the Parkinson's Foundation announced an investment of nearly USD 3 million in 33 research grants aimed at advancing the understanding and treatment of Parkinson's disease (PD). This funding will support innovative research projects focusing on various aspects of PD, including its causes, progression, and potential therapies. The grants are part of the Foundation's commitment to fostering scientific advancements that can lead to improved patient outcomes. This financial backing is vital for shaping the treatment landscape for neurological disorders and driving positive changes in patient care.
Furthermore, the increasing accessibility of these advanced devices to patients and healthcare professionals has further increased their adoption. Expanding reimbursement is improving patient access to these advanced therapies. In recent years, healthcare systems have increasingly acknowledged the effectiveness of neuromodulation devices in managing chronic pain, neurological disorders, and various other medical conditions, which has led many healthcare payers to include these devices in their coverage policies. For instance, in February 2024, Nerivio Remote Electrical Neuromodulation (REN) wearable by Theranica became the first non-pharmacological migraine treatment to get commercial coverage in the U.S. from Highmark Inc. The wearable offers acute and preventive treatment options, demonstrating significant clinical benefits in reducing migraine symptoms. Thus, the growing acceptance of neuromodulation therapies among payers is driving market growth.
Significant funding from government and private agencies plays a crucial role in advancing the understanding of neurological disorders and improving treatment options. By allocating resources to research initiatives, governments actively facilitate groundbreaking discoveries, encourage technological innovations, and promote the development of more effective neuromodulation technologies. For instance, in August 2024, the Parkinson's Foundation announced an investment of nearly USD 3 million in 33 research grants aimed at advancing the understanding and treatment of Parkinson's disease (PD). This funding will support innovative research projects focusing on various aspects of PD, including its causes, progression, and potential therapies. The grants are part of the Foundation's commitment to fostering scientific advancements that can lead to improved patient outcomes. This financial backing is vital for shaping the treatment landscape for neurological disorders and driving positive changes in patient care.
Furthermore, the increasing accessibility of these advanced devices to patients and healthcare professionals has further increased their adoption. Expanding reimbursement is improving patient access to these advanced therapies. In recent years, healthcare systems have increasingly acknowledged the effectiveness of neuromodulation devices in managing chronic pain, neurological disorders, and various other medical conditions, which has led many healthcare payers to include these devices in their coverage policies. For instance, in February 2024, Nerivio Remote Electrical Neuromodulation (REN) wearable by Theranica became the first non-pharmacological migraine treatment to get commercial coverage in the U.S. from Highmark Inc. The wearable offers acute and preventive treatment options, demonstrating significant clinical benefits in reducing migraine symptoms. Thus, the growing acceptance of neuromodulation therapies among payers is driving market growth.
Neuromodulation Devices Market Report Highlights
- Spinal cord stimulators held the largest market share of around 39.67% in 2024. Spinal cord stimulation devices are primarily used for patients without sufficient pain relief from non-surgical pain treatments.
- Parkinson’s disease held the largest market share of around 26.90% in 2024. The rising prevalence of Parkinson's disease, coupled with the increasing acceptance of deep brain stimulation as an effective treatment option, is expected to drive segment growth.
- Hospitals & Ambulatory Surgery Centers (ASC) held the largest market share in 2024 and the same segments are expected to show fastest growth during the forecast period.
- North America neuromodulation devices market dominated with a share of 43.68% in 2024, owing to increase in the prevalence of various neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, and epilepsy, and a rise in the demand for minimally invasive neurological procedures.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Neuromodulation Devices Variables, Trends & Scope
Chapter 4. Neuromodulation Devices Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)
Chapter 5. Neuromodulation Devices Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)
Chapter 6. Neuromodulation Devices Market - Segment Analysis, by End Use, 2018 - 2030 (USD Million)
Chapter 7. Neuromodulation Devices Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Abbott
- Medtronic
- Boston Scientific Corporation
- Nexstim
- LivaNova PLC
- Neuropace Inc.
- Nevro Corporation
- electroCore, Inc.
- Axonics, Inc.
- Laborie
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 120 |
Published | November 2024 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 5.79 Billion |
Forecasted Market Value ( USD | $ 10.39 Billion |
Compound Annual Growth Rate | 8.5% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |